BOVNF (BioInvent International AB) Shiller PE Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOVNF BioInvent International AB BOVNF
37 GF Score
Price $3.29
GF Value $1.09
! 5 Warning Signs
View Full Analysis

What is BioInvent International AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioInvent International AB  (OTCPK:BOVNF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BioInvent International AB Shiller PE Ratio Related Terms


BioInvent International AB Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Shiller PE Ratio Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioInvent International AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BOVNF vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, BioInvent International AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Shiller PE Ratio falls into.


BOVNF
37GF Score
BioInvent International AB BOVNF
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioInvent International AB's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, BioInvent International AB's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.1995/134.6100*134.6100
=-0.200

Current CPI (Jun. 2026) = 134.6100.

BioInvent International AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.288 101.138 -0.383
201612 -0.054 102.022 -0.072
201703 -0.192 102.022 -0.254
201706 -0.223 102.752 -0.292
201709 -0.211 103.279 -0.274
201712 -0.324 103.793 -0.420
201803 -0.242 103.962 -0.313
201806 -0.339 104.875 -0.435
201809 -0.164 105.679 -0.209
201812 -0.252 105.912 -0.321
201903 -0.201 105.886 -0.256
201906 -0.182 106.742 -0.230
201909 -0.190 107.214 -0.238
201912 -0.208 107.766 -0.260
202003 -0.165 106.563 -0.208
202006 -0.171 107.498 -0.214
202009 -0.113 107.635 -0.141
202012 0.084 108.296 0.105
202103 -0.231 108.360 -0.287
202106 -0.116 108.928 -0.144
202109 -0.124 110.338 -0.151
202112 -0.152 112.486 -0.182
202203 -0.124 114.825 -0.145
202206 0.291 118.384 0.331
202209 -0.095 122.296 -0.104
202212 -0.112 126.365 -0.120
202303 -0.107 127.042 -0.114
202306 -0.127 129.407 -0.133
202309 -0.100 130.224 -0.103
202312 -0.138 131.912 -0.141
202403 -0.114 132.205 -0.116
202406 -0.195 132.716 -0.198
202409 -0.142 132.304 -0.144
202412 -0.165 132.987 -0.167
202503 -0.166 132.825 -0.168
202506 0.061 133.699 0.061
202509 -0.206 133.480 -0.208
202512 -0.203 133.380 -0.205
202603 -0.198 133.550 -0.200
202606 -0.200 134.610 -0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioInvent International AB (BOVNF) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be overvalued. The current stock price of $3.29 is trading 201.7% above its estimated GF Value™ of $1.09.

Key valuation signals for BOVNF:

  • Shiller PE Ratio:
  • GF Value™: $1.09 vs. price of $3.29 (201.7% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
37GF Score

Get the complete analysis for BOVNF

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$1.09
GF Value